Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.

Quach, H; Horvath, N; Cannell, P; Mikhael, J R; Butcher, B E; Prince, H M

Quach, H; Horvath, N; Cannell, P; Mikhael, J R; Butcher, B E; Prince, H M.

Affiliation

Quach H; Department of Haematology and Clinical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Victoria. hang.quach@petermac.org

Intern Med J ; 39(5): 290-5, 2009 May.

Article in En | MEDLINE | ID: mdl-19371392

Subject(s)

Boronic Acids/therapeutic use; Multiple Myeloma/drug therapy; Pyrazines/therapeutic use; Adult; Aged; Aged, 80 and over; Australia/epidemiology; Boronic Acids/adverse effects; Bortezomib; Cohort Studies; Female; Gastrointestinal Diseases/chemically induced; Gastrointestinal Diseases/epidemiology; Humans; International Cooperation; Male; Middle Aged; Multiple Myeloma/epidemiology; Multiple Myeloma/prevention & control; New Zealand/epidemiology; Pyrazines/adverse effects; Recurrence; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 / 3_ND Database: MEDLINE Main subject: Pyrazines / Boronic Acids / Multiple Myeloma Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Oceania Language: En Journal: Intern Med J Year: 2009 Document type: Article

Fulltext

XML

PubMed Links

Search on Google